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Abstract 
Background: Hereditary angioedema (HAE) is a rare but serious condition characterized by recurrent spontaneous 
attacks of angioedema affecting superficial tissues of upper respiratory and gastrointestinal tracts. The potentially fatal 
and disfiguring nature of HAE impacts the health‑related quality of life (HRQoL) of patients with this condition.
Objectives: To assess the health‑related quality of life of Canadian patients with HAE using the 36‑item Short‑Form 
Health Survey (SF‑36v2).
Methods: Twenty‑one patients living in Canada over age 18 with known diagnosis of hereditary angioedema due to 
C1‑INH deficiency (HAE), completed the SF‑36v2 (generic HRQoL questionnaire). Results were compared to Canadian 
normative data by converting the SF‑36 scores into z scores.
Results: The SF‑36v2 showed a significant reduction in general health (p = 0.0063) in patients with HAE when 
compared with healthy Canadians. Percentage of patients with z scores below 0.8 (large effect) was 47.6% for general 
health subscale, 33.3% for bodily pain and vitality subscales and 28.6% for physical component scores. Mean scores of 
eight dimensions ranged from 57.7 to 88.9. Mean Physical and mental component scores were 49.1 and 50.4. Internal 
consistency of evaluation was demonstrated by Cronbach’s alpha value above 0.7 for all scales. General perception of 
health was significantly different in these patients, compared to Canadian normative data.
Conclusions: This study of Canadian patients with HAE shows that General Health is most frequently affected fol‑
lowed by Bodily Pain and Vitality, as measured by SF‑36v2. The SF‑36v2 offers valuable insight to assess quality of life 
in patients with HAE, however a larger number of Canadian patients and specific tools for assessment are needed for 
better evaluation.
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Background
Hereditary angioedema (HAE) is a rare but serious con-
dition due to a deficiency in serine protease inhibitor C1 
inhibitor (C1INH), leading to accumulation of bradykinin 
[1]. It is characterized by recurrent attacks of swelling 
affecting any part of the body, most commonly involving 
the extremities, face, genitals, gastrointestinal tract and 
upper airways. HAE is an autosomal dominant condition 
caused by mutations in the SERPING1 gene, with 25% of 
cases representing a de novo mutation, without a fam-
ily history of disease [1, 2]. The estimated prevalence of 
HAE is between 1:30,000 and 1:80,000, with no predilec-
tion for gender, race or ethnicity [1].
Episodes of swelling follow a stereotypic pattern in 
which worsening of bradykinin-mediated edema occurs 
over 24 h, peaks and slowly resolves over the subsequent 
48–72 h [1, 3]. Certain trigger factors have been identi-
fied including emotional stress, local trauma, dental or 
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medical procedures, infection, menstruation and the use 
of hormonal contraception [1, 2].
Despite this, severity of attacks remains unpredictable 
at onset and if affecting the upper airways, can lead to 
obstruction, asphyxiation and death [4].
Gastrointestinal attacks can cause significant pain and 
often are mistaken for acute abdomen, leading to unnec-
essary surgical intervention [5]. Edema affecting the skin 
and extremities causes disfigurement and if severe, com-
partment syndrome [1].
The unpredictable, potentially fatal as well as disfig-
uring nature of the disease impacts the health-related 
quality of life (HRQoL) of patients with this condition, 
however few publications have described the quality of 
life in patients with HAE. The Short Form 36 (SF-36v2) is 
a standardized patient reported survey of patient health, 
and is a measure of health status commonly used in 
health economics.
The aim of this study was to assess the health-related qual-
ity of life of Canadian patients with hereditary angioedema 
using the 36-item Short-Form Health Survey (SF-36v2).
Methods
Ethical aspects
Study protocol was approved by the Research and Ethics 
Board of St. Michael’s Hospital, Toronto and the Faculty 
of Medicine at the University of Toronto. Patients were 
recruited through the Canadian HAE patient network 
and treating physicians across Canada. Informed consent 
was obtained from all patients before study question-
naires were completed.
Patient population
Twenty-one patients living in Canada over the age of 18 
with a known laboratory confirmed diagnosis of heredi-
tary angioedema due to C1-INH deficiency (HAE) were 
included in the study (Table 1).
Data collection
Patients completed the generic SF‑36v2
SF-36v2 is a generic health questionnaire measuring 
eight health domains including physical functioning 
(PF), limitations in daily role functioning due to physi-
cal problems (RP), bodily pain (BP), general health 
(GH), vitality (VT), social functioning (SF), limita-
tions in daily role functioning due to emotional prob-
lems (RE), mental health (MH) as well as an item asking 
respondents about health change over the past year. 
Scores for each domain can range from 0 to 100, higher 
scores indicating better health state. Scores on each 
scale were calculated based on the ‘half item rule’. Two 
summary scores were also calculated from the eight 
domains: the physical component summary (PCS) and 
the mental health component summary (MCS). Sum-
mary scores are normalized to age-matched controls 
and scored to have a mean of 50 and standard deviation 
of 10.
Statistical analysis
Descriptive statistics for demographic information were 
calculated. Results were compared to Canadian norma-
tive data by converting the SF-36v2 scores into z-scores. 
Z-scores with values above 0.80 are considered to have 
large effects.
Each person’s score was standardized by subtracting 
the mean value and dividing by the standard deviation for 
the Canadian norms of the same age and gender group 
[6]. This z-score has a mean of 0 and a standard devia-
tion of 1. This method of examining differences between 
samples is similar to calculating effect sizes [7]. Thus, the 
z-scores can be interpreted in the same way with values 
above 0.80 considered large effects. We used a one-sam-
ple t test, with zero as test value, to determine if signifi-
cant differences (p < 0.05) from age- and gender-matched 
Canadian norms existed.
Table 1 Descriptive analysis and Cronbach’s alpha values for the eight subscales and two summary scales of the SF-36 
in 21 hereditary angioedema patients
Domain Minimum Maximum Median Mean Standard deviation Cronbach’s alpha Floor n (%) Ceiling n (%)
Physical functioning (PF) 40.00 100.00 95.00 87.86 16.25 0.86 0 (0) 8 (38.10)
Role physical (RP) 0.00 100.00 93.75 84.23 23.19 0.91 1 (4.76) 7 (33.33)
Bodily pain (BP) 22.00 100.00 74.00 67.90 21.79 0.89 0 (0) 3 (14.29)
General health (GH) 5.00 100.00 62.00 61.05 23.39 0.84 0 (0) 1 (4.76)
Vitality (VT) 25.00 81.25 62.50 57.74 18.32 0.83 0 (0) 0 (0)
Social functioning (SF) 0.00 100.00 100.00 85.12 27.28 0.95 1 (4.76) 13 (61.90)
Role emotional (RE) 16.67 100.00 100.00 88.89 24.49 0.94 0 (0) 16 (76.19)
Mental health (MH) 25.00 90.00 80.00 76.19 16.95 0.89 0 (0) 0 (0)
Physical summary (PCS) 34.17 63.21 48.62 49.13 N/A N/A N/A
Mental summary (MCS) 15.99 65.88 54.60 50.35 N/A N/A N/A
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Cronbach’s alpha was used to assess the internal con-
sistency of each subscale and a value equal to or greater 
than 0.7 was considered acceptable. Data were analyzed 
using SAS software, version 9.4 (SAS Institute, Cary, 
NC).
Results
Twenty-one patients were included in the study. The 
majority of patients were female (20 =  95.2%), from an 
urban area (15  =  71.4%), and had an education level 
above high school (15  =  71.4%) and a medium–low 
socio-economic level (8  =  44.4%). The mean age was 
42.3 years (SD 13.7 years).
The percent of patients with a z score below 0.8 (large 
effect) was 47.6% for General Health subscale, 33.3% 
for Bodily Pain and Vitality subscales, and 28.6% for 
the physical component summary score. The SF-36v2 
showed there was a significant reduction in general 
health (p  =  0.0063) in patients with hereditary angi-
oedema (HAE) when compared with healthy Canadi-
ans (Table  2). The mean scores of the eight dimensions 
ranged from 57.7 to 88.9. The mean Physical and Mental 
Component Summary Scores were 49.1 and 50.3. Gen-
eral perception of health was significantly different in this 
patient population, compared to Canadian normative 
data. There were no significant relationships between SF-
36v2 scores and age or education level.
Cronbach’s alpha exceeded 0.70 for all scales, very high 
ceiling effects occurred for the SF-36 RE (76.2%) and 
SF subscales (61.9%) followed by the PF (38.1%) and RP 
(33.3%) subscales. Cronbach’s alpha for these four sub-
scales ranged from 0.86 to 0.95 while the range for the 
other four subscales was 0.83–0.89. Two items (sf8 and 
sf3d) each had one missing value (4.8%).
Discussion
Hereditary angioedema is a rare but serious condition, in 
which affected patients suffer a significant burden of dis-
ease, similar to that of severe asthma or Crohn’s disease 
[8]. Additionally, patients with HAE deal with the uncer-
tainties and unpredictable nature of episodic attacks of 
angioedema.
Few studies have evaluated the quality of life in 
patients with HAE [3, 9]. In this study, Canadian patients 
exhibited an impaired quality of life, as measured by the 
standardized SF-36v2, particularly in the domains of 
general health, bodily pain and vitality. In previous data, 
patients with HAE reported decreased mental and phys-
ical health as well as social effects compared to a nor-
mal population, in keeping with our study of Canadian 
patients [3, 9, 10].
In both the study by Gomide [10] and our study, the 
SF-36 subscales with the lowest median values were 
General Health, Bodily Perception and Vitality (40, 52, 
and 60 respectively for the Gomide [10] study and 62.0, 
74.0, and 62.5 respectively for our study). The median 
value for the SF subscale differed between the two stud-
ies (median value of 50 vs. 100). A more recent Danish 
study by Aabom et al. showed mean SF-36v2 scores cor-
responding with population norms, likely explained by 
differences in treatment options and access to around the 
clock counseling for Danish patients [11].
The high Cronbach’s alpha for all SF-36 scales indicates 
a high internal consistency. However, the high alpha coef-
ficients observed might be partly due to the ceiling effects 
observed in some subscales (mainly RE and SF, but also 
PF and RP). These ceiling effects could be related to a low 
sensitivity of these subscales or to nearly no affection of 
these subscales in Canadian HAE patients.
Table 2 SF36v2 HAE patients compared to Canadian normative data [6]
a From one sample t test










Mean (sd) p valuea
Physical functioning 14.3 14.3 23.8 42.9 4.8 0.06 (0.73) 0.6926
Role‑physical 4.8 4.8 61.9 28.6 0.0 0.08 (0.71) 0.6197
Bodily pain 33.3 9.5 42.9 0.0 14.3 −0.29 (0.98) 0.1991
General health 47.6 4.8 33.3 4.8 9.5 −0.95 (1.42) 0.0063
Energy/vitality 33.3 9.5 23.8 28.6 4.8 −0.29 (1.05) 0.2207
Social functioning 14.3 4.8 19.1 42.9 19.1 0.02 (1.40) 0.9607
Role‑emotional 14.3 0.0 9.5 76.2 0.0 0.20 (0.81) 0.2669
Mental health 14.3 4.8 33.3 19.1 28.6 0.02 (1.13) 0.9303
Physical component scale 28.6 14.3 33.3 9.5 14.3 −0.23 (0.99) 0.3027
Mental component scale 19.1 0.0 33.3 33.3 14.3 −0.05 (1.39) 0.8825
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Health-related quality of life questionnaires are devel-
oped to evaluate individual patient health status, assess 
the cost-effectiveness of an intervention or treatment, 
and to monitor disease burden. Several questionnaires 
have been developed to evaluate health related quality of 
life and help establish resource allocation [12]. The stand-
ardized SF-36v2 questionnaire can be a useful tool in the 
assessment of quality of life in patients with HAE, which 
allows comparison to other diseases, however a need 
exists for disease-specific surveys, to serve as a more pre-
cise indicator of disease burden. Disease-specific surveys 
can serve as a point of comparison with generic question-
naires and further evaluate particular aspects of disease 
severity. A specific HAE QOL questionnaire has been 
developed in Spain and translated and validated in other 
countries [13, 14].
Conclusion
This study of Canadian patients with HAE shows that 
General Health is most frequently affected followed by 
Bodily Pain and Vitality, as measured by SF-36v2. The 
SF-36v2 offers valuable insight to assess quality of life in 
patients with HAE, however a larger number of Canadian 
patients and specific tools for assessment are needed for 
better evaluation.
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